HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Reduction-Responsive and Multidrug Deliverable Albumin Nanoparticles: An Antitumor Drug to Abraxane against Human Pancreatic Tumor-Bearing Mice.

Abstract
Many macromolecular antitumor drugs were developed based on the enhanced permeability and retention (EPR) effect, for example, albumin-bound paclitaxel nanoparticles (nab-PTX and Abraxane) and pegylated liposomal doxorubicin (Doxil). However, these EPR effect-based therapeutic systems are less effective in malignant tumors with low vascular permeability, such as pancreatic tumors. Because the EPR effect depends on nanoparticles' size, we first determined nanoparticles' size associated with a high tumor-targeting rate in a human pancreatic tumor xenograft model with low vascular permeability. Abraxane appears to behave as an albumin monomer (7 nm) in the blood circulation following intravenous injection. The in vitro and in vivo tumor-targeted delivery and antitumor activity of PTX-loaded albumin nanoparticles were significantly improved by optimizing the mean nanoparticle diameter to 30 nm. Furthermore, nitric oxide was added to 30 nm PTX-loaded albumin nanoparticles to examine the feasibility of albumin nanoparticles as a platform for multiple drug delivery. Their antitumor effect was evaluated in an orthotopic transplantation mouse model of a human pancreatic tumor. The nitric oxide PTX-loaded 30 nm albumin nanoparticle treatment on model mice achieved a significantly higher survival rate than Abraxane treatment. These findings suggest that 30 nm albumin nanoparticles have a high therapeutic effect as a useful platform for multiple drugs against human pancreatic tumors.
AuthorsNaoki Hirakawa, Yu Ishima, Ryo Kinoshita, Ryuto Nakano, Victor Tuan Giam Chuang, Hidenori Ando, Taro Shimizu, Keiichiro Okuhira, Toru Maruyama, Masaki Otagiri, Tatsuhiro Ishida
JournalACS applied bio materials (ACS Appl Bio Mater) Vol. 4 Issue 5 Pg. 4302-4309 (05 17 2021) ISSN: 2576-6422 [Electronic] United States
PMID35006842 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Albumin-Bound Paclitaxel
  • Antineoplastic Agents
  • Biocompatible Materials
Topics
  • Albumin-Bound Paclitaxel (chemical synthesis, chemistry, pharmacology)
  • Animals
  • Antineoplastic Agents (chemical synthesis, chemistry, pharmacology)
  • Biocompatible Materials (chemical synthesis, chemistry, pharmacology)
  • Cell Line, Tumor
  • Cell Survival (drug effects)
  • Drug Screening Assays, Antitumor
  • Humans
  • Materials Testing
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Nanoparticles (chemistry)
  • Neoplasms, Experimental (drug therapy, pathology)
  • Pancreatic Neoplasms (drug therapy, pathology)
  • Particle Size

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: